For the roughly 200 million people worldwide who take a statin every day, the routine is deceptively simple: swallow a pill, repeat tomorrow, repeat forever. In practice, nearly half of patients prescribed statins stop taking them within a year, leaving their LDL cholesterol uncontrolled and their cardiovascular risk elevated. Now, data from a late-stage clinical trial suggest a radically different model: a single injection of a gene-silencing drug called inclisiran that held LDL cholesterol down for a full 12 months.
The drug is not hypothetical. Inclisiran is already approved by the U.S. Food and Drug Administration and sold under the brand name Leqvio, manufactured by Novartis. What the latest trial data reveal is just how long a single dose can work, and how that durability could reshape cholesterol treatment for millions of patients.
One shot, one year of lower LDL
The core evidence comes from the ORION-1 trial, a randomized, placebo-controlled study published in JAMA Cardiology. Patients who received a single subcutaneous injection of inclisiran experienced time-averaged LDL-C reductions of 29.5% to 38.7% over one year, depending on dose. Those who received a second injection at day 90 saw even steeper drops, with time-averaged reductions of 29.9% to 46.4% across the same follow-up period.
Inclisiran works by deploying small interfering RNA (siRNA) to silence the gene that produces PCSK9, a protein the liver uses to regulate how much LDL cholesterol stays in the bloodstream. By shutting down PCSK9 production inside liver cells, the drug allows those cells to pull more LDL out of circulation. Because the RNA machinery persists in hepatocytes for months, a single dose sustains its effect far longer than any daily pill.
Long-term follow-up data reinforce that picture. The ORION-8 trial, an open-label extension study published in the European Heart Journal in 2024, showed that patients who continued receiving inclisiran injections roughly every six months maintained potent LDL-C lowering over an extended period. Participants consistently hit treatment targets with just two shots per year, supporting the case that twice-yearly dosing is practical for sustained cholesterol management.
How inclisiran differs from statins and earlier PCSK9 drugs
The distinction matters because inclisiran is not the first drug to target PCSK9. Monoclonal antibodies like evolocumab (Repatha) and alirocumab (Praluent) have been available for years, and both have proven cardiovascular outcomes data behind them. But those drugs require patients to self-inject every two to four weeks, a frequency that creates its own adherence challenges.
Statins, meanwhile, work through a completely different pathway. They inhibit an enzyme involved in cholesterol synthesis, which indirectly causes the liver to pull more LDL from the blood. They are cheap, well-studied, and backed by decades of outcomes data showing fewer heart attacks and strokes. Their weakness is the daily pill burden and side effects, particularly muscle pain, that drive many patients to quit.
Inclisiran occupies a middle ground: it targets PCSK9 like the monoclonal antibodies but requires far fewer injections, and it shifts the compliance burden from the patient to the clinic. A healthcare provider administers the shot, so there is no prescription bottle sitting forgotten on a nightstand.
The big unanswered question: does it prevent heart attacks?
Here is the gap that cardiologists and patients need to understand. The ORION-1 trial and its extensions measured LDL-C levels, not hard cardiovascular outcomes like heart attacks, strokes, or death. LDL-C reduction is a well-validated surrogate marker. Decades of statin research have established that lowering LDL-C translates into fewer cardiac events. But the direct proof that inclisiran-driven LDL-C reduction produces the same clinical benefit has not yet been published.
That proof is being sought. The ORION-4 trial, a large cardiovascular outcomes study enrolling roughly 15,000 patients across multiple countries, is designed to answer exactly this question. Results are anticipated in the coming years. Until ORION-4 reports, the assumption that inclisiran will reduce heart attacks and strokes at the same rate as equivalent LDL-C lowering from statins remains scientifically reasonable but unconfirmed.
Real-world hurdles: cost, access, and clinic logistics
Even a highly effective therapy can fail patients if they cannot afford it or access it. Inclisiran’s list price in the United States is significantly higher than generic statins, which cost as little as a few dollars per month. Insurance coverage varies, and some payers impose prior-authorization requirements that delay or block access, particularly for patients who are not classified as high-risk.
There is also a logistical question that clinical trials cannot fully answer. Twice-yearly clinic visits sound manageable, but for patients who already struggle to attend routine appointments, especially those in rural areas or without reliable transportation, the shift from a home-based pill to a clinic-based injection could introduce new barriers. Health systems will need scheduling infrastructure and outreach protocols to ensure patients return on time for each dose.
On the horizon: permanent gene editing for cholesterol
While inclisiran silences the PCSK9 gene temporarily, a more experimental program aims to shut it off permanently. VERVE-101, a base-editing therapy now in Eli Lilly’s pipeline following its acquisition of Verve Therapeutics, is delivered by a single IV infusion and designed to make a precise, permanent change to the PCSK9 gene at the DNA level.
A phase 1b trial is currently enrolling patients with familial hypercholesterolemia and established cardiovascular disease to evaluate safety, dosing, and early biological activity. No efficacy results have been published from this trial as of June 2026.
The appeal is obvious: one infusion, permanent LDL-C reduction, no repeat dosing ever. But the risks are proportionally larger. Unlike inclisiran, whose effects wear off and can be discontinued, a permanent genetic edit offers little room for reversal if unexpected problems surface years later. Long-term off-target effects of base editing in living patients have no established human safety record. Regulators will demand extensive follow-up data before approving a one-time genetic alteration for a condition that can already be managed with reversible therapies.
What the strength of the evidence actually tells us
Not all clinical data carry equal weight, and readers following this space should understand the hierarchy at play. The ORION-1 trial is a randomized, controlled study with prespecified endpoints and blinded assessment, the gold standard for measuring a drug’s biological effect. Its LDL-C reduction figures are robust for the population studied.
The ORION-8 extension adds valuable durability data but uses an open-label design, meaning patients and investigators knew what treatment was being given. Open-label extensions tend to retain patients who tolerate and respond well to a drug, which can make results appear stronger than they would in a broader population. That said, the consistency of LDL-C lowering across ORION-8 supports the conclusion that inclisiran’s effect is not a short-lived anomaly.
The VERVE-101 listing on ClinicalTrials.gov is a protocol document. It confirms what is being tested and in whom, but it contains no results. Any projections about the magnitude or permanence of LDL reduction from VERVE-101 remain speculative until peer-reviewed data are published.
Where cholesterol treatment goes from here
Inclisiran is already approved, already in clinics, and already producing year-long LDL-C reductions from a single shot. For patients who cannot or will not take a daily statin, that is a meaningful advance. What it still needs is proof from ORION-4 that those lower cholesterol numbers translate into fewer heart attacks and strokes, the outcome that ultimately matters.
Gene editing with VERVE-101 represents a bolder bet: the possibility of curing high cholesterol with one treatment rather than managing it indefinitely. But that promise is years away from validation, and the safety bar for permanently altering a patient’s DNA to address a treatable risk factor will be extraordinarily high.
For now, the practical picture is this: inclisiran gives clinicians a powerful new tool for patients who struggle with daily statins, while the broader question of whether a shot can do everything a pill does, including preventing cardiovascular events, awaits its definitive answer.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
